77MO A phase I trial of IMA203CD8, a PRAME-directed TCR T cell therapy in PRAME-positive solid tumors

20250 citationsJournal Articlegold Open Access

Authors

Good health and well-being

Published in: Immuno-Oncology Technology

Volume 28, pp. 101162-101162

Field-Weighted Citation Impact: 0.00